to 87% and from 30% to 47%, respectively. 1,3 Unlike other sarcomas, the high rate of nodal metastasis (14-60%) is characteristic of ES. 1,3 Whereas the occurrence of lymph node metastasis in sarcoma is recognized as a rare event (2.6%), 4 many types of carcinoma show the frequent lymph node metastasis (20-35%). 5 The frequent nodal metastasis of ES implies that ES could have the biological potential as well as morphological appearance shared by epithelial neoplasms.FGFRs and their ligands, 23 members of FGF family, are involved in developmental processes, angiogenesis, wound healing and tumorigenesis. Four FGFRs (FGFR1-4) have been identified in mammals. Alternative splicing of mRNA in FGFR1-3 generates two receptor isoforms, IIIb and IIIc. The expression of the FGFR transcriptional variant is tightly regulated by cell lineage, and these isoforms show quite different ligand-binding specificities. 2 FGFR2-IIIb is a specific receptor of FGF-7, also designated keratinocyte growth factor, whose expression is restricted to epithelial cells, whereas isotype IIIc of FGF1-3 mainly serves as the receptor for various FGF members in mesenchymal cells. Such specificity gives rise to lineage-specific behaviour compared with other growth factor receptors universally expressed in a wide range of cells. The expression of FGFR2-IIIb in ES implied epithelial differentiation accompanied by a basal mesenchymal nature. The in vitro experiments indeed showed that ES cells were subject to a mitogenic effect of FGF-7, indicating that FGFR2-IIIb could functionally render ES the behaviour shared by cells of epithelial origin. 6 Although it is a future subject to be addressed whether FGFR2-IIIb is commonly expressed in ES, the specific expression of FGFR2-IIIb could partially evidence the carcinomatous behaviour of ES including the frequent nodal metastasis.
References1 Assier H, Bastugigarin S, Revel J, Roujeau JC. Clinical classification of cases of Toxic epidermal necrolysis, Stevens-Johnson Syndrome. Arch Dermatol 1993; 129: 92-96. 2 Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acd Dermatol 2007; 56: 181-200. 3 Mockenhaupl M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevans-Johnson Syndrome and Toxic Epidermal Necrolysis in new users of antileptics. Neurology 2005; 64: 1134-1138. 4 Eaye O, Wechslor Roujeau JC. Cell-mediated immunologic mechanism and severity of TEN. Arch Dermatol 2005; 141: 775-776. 5 Mackie RM. Cutaneous Lymphomas and lymphocytic infiltrates. In: Rook A, Wilkinson DS, Ebling EJG, eds. Text book of Dermatology, 6th edn. Oxford Blackwell science, 1998: 2374-2382. 6 Miller RA, Coleman CN, Fawcett HD, Hoppe RT, McDougall IR. Sezary Syndrome: a model for migration of T Lymphocytes to the skin. N Eng J Med 1980; 303: 89-92. 7 Nikkels AJ, Sadzot-Delvaux C. Absence of intercellular adhesion molecule 1 expression in varicella zoster virus-infected keratinocytes during herpes zoster. Another immune evasion strategy? Am